"10.1371_journal.pone.0082222","plos one","2014-01-03T00:00:00Z","Silvana Romio; Daniel Weibel; Jeanne P Dieleman; Henning K Olberg; Corinne S de Vries; Cormac Sammon; Nick Andrews; Henrik Svanström; Ditte Mølgaard-Nielsen; Anders Hviid; Maryse Lapeyre-Mestre; Agnès Sommet; Christel Saussier; Anne Castot; Harald Heijbel; Lisen Arnheim-Dahlström; Par Sparen; Mees Mosseveld; Martijn Schuemie; Nicoline van der Maas; Bart C Jacobs; Tuija Leino; Terhi Kilpi; Jann Storsaeter; Kari Johansen; Piotr Kramarz; Jan Bonhoeffer; Miriam C J M Sturkenboom","Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom; Health Protection Agency, London, United Kingdom; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark; Department of Clinical Pharmacology, Toulouse University Hospital and Institut national de la santé et de la recherche médicale, Toulouse, France; French National Agency for Medicines and Health Products Safety, Saint Denis, France; Medical Doctor - Consultant, Paris, France; Department of Vaccinology, Swedish Institute for Infectious Disease Control, Solna, Sweden; Department Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland; Department of Vaccines, Norwegian Institute of Public Health, Oslo, Norway; Surveillance and Response Support Unit, European Centre for Disease Prevention and Control, ECDC, Stockholm, Sweden; Brighton Collaboration Foundation, Basel, Switzerland; Department of Infectious Diseases and Vaccinology, University Childrens Hospital, Basel, Switzerland","Wrote the paper: SR DW JPD HKO MCJMS. Study design, data management, data analysis, interpretation of data and results, and reviewing of manuscript: SR DW JPD HKO CSDV CS NA HS DMN AH MLM AS CS AC HH LAD PS MM MS NVDM BCJ TL TK JS KJ PK JB MCJMS. Main pooled statistical data analysis: SR. Main pooled statistical data analysis, advisory role: NA. Scientific coordination of VAESCO consortium: DW JB MCJMS. Development of software for data collection, harmonization, and aggregation across databases: MS MM. European Centre for Disease Prevention and Control, project leader for the GBS and pandemic vaccines: KJ PK.","Silvana Romio, Daniel Weibel, Henning K Olberg, Nick Andrews, Henrik Svanström, Ditte Mølgaard-Nielsen, Anders Hviid, Maryse Lapeyre, Agnès Sommet, Christel Saussier, Anne Castot, Harald Heijbel, Lisen Arnheim-Dahlström, Mees Mosseveld, Nicoline van der Maas, Bart C Jacobs, Tuija Leino, Jann Storsaeter, Kari Johansen, and Piotr Kramarz have no conflicts of interest. Jeanne P Dieleman has been involved in studies for pharmaceutical companies (i.e., GSK, Sanofi, Astra-Zeneca, Pfizer). None of these had any conflict with the present study. The affiliation (i.e. University of Bath) of Corinne S de Vries and Cormac Sammon has research and consulting contracts in place with Novartis vaccines and with GSK pharmaceuticals. The authors do not personally benefit from these contracts; all financial compensation is to the University of Bath and not to the authors. Martijn Schuemie was employed at the Erasmus University Medical Center, Rotterdam at the time of the study. Since January 1st 2013 (after completion of the study), he is employed at Janssen R&D. Terhi Kilpi is a principal investigator of a nationwide Finish effectiveness study of the 10-valent pneumococcal conjugate vaccine, a collaborative study, for which her institute has received funding from GSK. Par Sparen received a grant from Glaxo Smith Kline in 2010 to for a retrospective, observational register based cohort study to evaluate the safety of GSK Biologicals H1N1 pandemic vaccine administered in Sweden according to local vaccination policy. Miriam CJM Sturkenboom: is head of a research group that occasionally conducts research for pharmaceutical companies including Pfizer, EliLilly, Boehringer, AstraZeneca and Novartis. None was related to this topic.This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Silvana Romio","SR",28,TRUE,NA,NA,NA,5,TRUE,FALSE,FALSE,0,NA,FALSE
